<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27347034</article-id><article-id pub-id-type="pmc">4907125</article-id><article-id pub-id-type="doi">10.3892/etm.2016.3312</article-id><article-id pub-id-type="publisher-id">ETM-0-0-3312</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Clinical effects of perazine ferulate tablets combined with eucalyptol limonene pinene enteric soft capsules for treatment of children with IgA nephropathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>LIU</surname><given-names>ZHIZHEN</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3312"/><xref rid="c1-etm-0-0-3312" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>PAN</surname><given-names>JINGMEI</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3312"/></contrib><contrib contrib-type="author"><name><surname>SUN</surname><given-names>CHUNLEI</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3312"/></contrib><contrib contrib-type="author"><name><surname>ZHOU</surname><given-names>JUAN</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3312"/></contrib><contrib contrib-type="author"><name><surname>LI</surname><given-names>NA</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3312"/></contrib></contrib-group><aff id="af1-etm-0-0-3312">Department of Pediatrics, Yidu Central Hospital of Weifang, Weifang, Shandong 262500, P.R. China</aff><author-notes><corresp id="c1-etm-0-0-3312"><italic>Correspondence to</italic>: Dr Zhizhen Liu, Department of Pediatrics, Yidu Central Hospital of Weifang, 4138 South Linglong Shan Road, Weifang, Shandong 262500, P.R. China, E-mail: <email>vkg778@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>09</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>09</day><month>5</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>12</volume><issue>1</issue><fpage>169</fpage><lpage>172</lpage><history><date date-type="received"><day>24</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>06</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Liu et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>The clinical effects of piperazine ferulate tablets combined with eucalyptol limonene pinene enteric soft capsules for treatment of children with IgA nephropathy were investigated. Sixty children with IgA nephropathy were included in the study and were randomly divided into the control (n=30) and observation (n=30) groups. The patients in the control group were treated with conservative or hormone therapy while patients in the observation group were treated with piperazine ferulate tablets combined with eucalyptol-limonene-pinene enteric soft capsules. Clinical effects were observed and compared. The total effective rate of the observation group was significantly higher than that of the control group, while the incidence of complications was significantly lower than that of the control group (p&#x0003c;0.05). Serum IgA and fibronectin levels of the observation group were significantly lower than those of the control group, while the level of C3 was significantly higher than that of the control group (p&#x0003c;0.05). In conclusion, piperazine ferulate tablets combined with eucalyptus enteric soft capsule constituted a safe and effective for the treatment of children with IgA nephropathy. The treatment was superior to conservative or hormone therapy, and thus worthy of clinical promotion.</p></abstract><kwd-group><kwd>piperazine ferulate tablets</kwd><kwd>eucalyptol-limonene-pinene enteric soft capsule</kwd><kwd>IgA nephropathy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The morbidity of IgA nephropathy in children is 0.8%. Most children have good prognosis, with &#x0003c;5% of child patients showing rapidly progressive glomerulonephritis that develops into renal failure (<xref rid="b1-etm-0-0-3312" ref-type="bibr">1</xref>). At present, IgA nephropathy is caused by the precipitation of circulating immune complexes that contain IgA in kidney, and the antigen in the complex may be associated with the virus and bacteria from the respiratory tract or gastrointestinal tract mucosa or certain components of food (<xref rid="b2-etm-0-0-3312" ref-type="bibr">2</xref>). The typical symptoms include hematuria (75%), albuminuria (73%), low fever (65%), kidney area percussion pain (65%), small vascular fibrous necrosis (55%), and edema (55%) (<xref rid="b3-etm-0-0-3312" ref-type="bibr">3</xref>). Treatment suggestions include good rest, anti-infection and symptomatic treatment, if necessary, combined with adrenal cortical hormone and immunosuppressive therapy (<xref rid="b4-etm-0-0-3312" ref-type="bibr">4</xref>).</p><p>In Chinese medicine, the processing, extraction, concentration and blending of certain components of some plants, produces piperazine ferulate tablets and eucalyptol-linonene-pinene enteric soft capsules. Previous findings confirmed that the two drugs can inhibit IgA from depositing in the kidney and can reduce the immune response (<xref rid="b5-etm-0-0-3312" ref-type="bibr">5</xref>).</p><p>In the present study, the safety and efficacy of a combination of the two drugs for the treatment of children with IgA nephropathy were also evaluated and clinical effects were compared with conventional western medicine to provide new ideas for clinical treatment.</p></sec><sec sec-type="subjects|methods"><title>Patients and methods</title><sec><title/><sec><title>Patients</title><p>Sixty children with IgA nephropathy were included in the study. Diagnostic criteria of IgA nephropathy included: i) Clinical symptoms such as gross hematuria, and proteinuria; ii) kidney tissue puncture immune pathological examinations: a) light microscope showed glomerular number &#x0003e;6; b) immune fluorescence showed characteristic changes, immunoglobulin dominated by IgA showed granular or lump-like diffuse deposits in glomerular mesangial region, and some deposits alongside capillary loop; and c) electron microscope showed mesangial cell proliferation, increased mesangial matrix with large lump-like electron dense deposits; and iii) excluded Henoch-Sch&#x000f6;nlein Purpura nephritis, lupus nephritis, sicca syndrome, psoriasis, ankylosing spondylitis, liver cirrhosis, hepatitis B or C virus infection and other secondary IgA nephropathy. Patients that conformed to the diagnostic criteria of IgA nephropathy and patients that were treated for the first time were also included in the study.</p><p>Exclusion criteria were, patients with nephrotic syndrome, acute nephritis, acute nephritis and renal failure; patients with uncontrolled infection, fever and diarrhea; patients with congenital malformation, hereditary metabolic disease, combined with other organ dysfunction and coagulation disorders; patients with allergic or intolerable to piperazine ferulate tablets and eucalyptol-linonene-pinene enteric soft capsule, with poor compliance.</p><p>After obtaining the approval of the Ethics Committee of the Yidu Central Hospital of Weifang (Shandong, China) and the informed consent of the parents or relatives, the patients were divided randomly into the control (n=30) and observation (n=30) group. The control group included 19 male and 11 female patients, with an age range of 6&#x02013;15 years, and an average of 12.3&#x000b1;4.2 years. The disease course ranged from 3 days to 2 months, and an average of 27.4&#x000b1;8.2 days. The observation group comprised 20 male and 10 female patients, with an age range of 5&#x02013;17 years and an average age of 13.6&#x000b1;5.5 years. The disease course ranged from 5 days to 2 months and an average of 26.3&#x000b1;7.7 days. Differences in gender, age and course of the two groups were not statistically significant (p&#x0003e;0.05).</p></sec><sec><title>Treatment methods</title><p>Patients in the control group were treated with conservative or hormone therapy. Conservative therapy included good rest, antiviral or antibiotic anti-infection, full course of treatment, and symptomatic treatments such as diet control, moderate depressurization, and protein reduction. The patients that failed conservative treatment used hormone or hormone combined with immunosuppressive therapy. Dosage regimen included the oral administration of prednisone, initial dose of 1 mg/kg.d, taken in the morning, maintained for 8 weeks and then gradually reduced the dose by 5 mg every week until 5 mg/day, followed by maintaining the dose for a total course of 6 months. During the treatment period, any complications were closely monitored and the dose or suspended medication were adjusted in a timely manner if necessary.</p><p>Patients in the observation group were treated using piperazine ferulate tablets combined with eucalyptol-limonene-pinene enteric soft capsules. Dosage regimen included 0.1 g piperazine ferulate tablets (50 mg/tablet; Chengdu Heand Pharmeuticals Co., Ltd., Chengdu, China), 3 times/day; and eucalyptol-limonene-pinene enteric soft capsule (KPC Pharmaceuticals, Inc., Kunming, China), 2 capsules/time, twice per day for 6 months. During the treatment period, the patients were closely monitored for any complications and dose or suspended medication was adjusted in a timely manner if necessary.</p></sec><sec><title>Observation indices</title><p>The differences of total efficiency, incidence of complication, serum IgA, fibronectin and complement C3 levels of the two groups were compared (<xref rid="tI-etm-0-0-3312" ref-type="table">Table I</xref>).</p></sec><sec><title>Detection of serum IgA, fibronectin and complement C3</title><p>Venous blood (5 ml) was drawn in the morning and centrifuged at 2,000 &#x000d7; g for 15 min to collect the supernatant for preservation at &#x02212;80&#x000b0;C. Kits of IgA, fibronectin and complement C3 were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). IgA was detected using ELISA and fibronectin and complement C3 were examined by single radial immunodiffusion, according to the supplier instructions.</p></sec><sec><title>Statistical analysis</title><p>SPSS 19.0 statistical software (SPSS Inc, Chicago, IL, USA) was used for statistical analysis and data were presented as mean &#x000b1; standard deviation. The comparison between groups was made by an independent sample t-test. Enumeration data were expressed as a percentage. The comparison between groups was made using the &#x003c7;<sup>2</sup> test. P&#x0003c;0.05 was considered to indicate a statistically significant difference.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Comparison of total efficiency and the incidence of complications</title><p>Twelve patients in the control group underwent expectant treatment and 18 cases underwent hormonal treatment. The total effective rate of the observation group was significantly higher compared to the control group. The incidence of complications was significantly lower compared to the control group (p&#x0003c;0.05).</p></sec><sec><title>Comparison of serum IgA, fibronectin and complement C3 levels</title><p>Prior to intervention, differences of serum IgA, fibronectin and complement C3 levels of the two groups were not statistically significant (p&#x0003e;0.05). After intervention, the indices of the two groups were improved and serum IgA and fibronectin levels of the observation group were significantly lower than those of the control group. Levels of complement C3 were significantly higher than that of the control group (p&#x0003c;0.05) (<xref rid="tII-etm-0-0-3312" ref-type="table">Table II</xref>).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>IgA nephropathy is accompanied by deposition of IgA and C3 deposition in kidney tissues. IgA is an important immunoglobulin that accounts for 15% of the total serum immunoglobulin (<xref rid="b6-etm-0-0-3312" ref-type="bibr">6</xref>). IgA deposition is parallel to pathological changes of glomerulus. IgA deposition in the mesangial area is accompanied by mesangial proliferation, and IgA deposition in the capillary is accompanied by the changes of blood vessel endothelium (<xref rid="b7-etm-0-0-3312" ref-type="bibr">7</xref>). Pathological factors that cause IgA deposition include (<xref rid="b3-etm-0-0-3312" ref-type="bibr">3</xref>,<xref rid="b4-etm-0-0-3312" ref-type="bibr">4</xref>,<xref rid="b7-etm-0-0-3312" ref-type="bibr">7</xref>): i) Entrance of an antigen into the body from mucosa to stimulate the IgA immune system. Antigen may be a microorganism or food such as egg albumin, bovine serum albumin, and casein; ii) abnormal IgA immune response results in the formation of poly IgA of high molecular weight; iii) poly IgA that contains antigens combines with fibronectin through static &#x003bb; chain or receptor FeaR and precipitates in kidney. IgA-fibronectin complex in serum was characteristic of IgA nephropathy; and iv) other IgA removal mechanisms such as liver damage or saturation.</p><p>Previous findings showed that IgA that precipitate in glomerulus of IgA nephropathy were mainly poly IgA (<xref rid="b8-etm-0-0-3312" ref-type="bibr">8</xref>). IgA nephropathy patients showed increased serum IgA1, poly IgA, and &#x003bb;-IgA1. The lymphoid B cells had &#x003b2;-1 and 33 galactose transferase deficiency, which led to O-type glycosylation of the IgA1 strand area and reduced galactolipin of chain end, which further affected the binding of IgA1 with oligo sialic acid protein receptor ASGPR in liver cells. The affected IgA removal increased the binding of IgA with other kidney tissues, leading to its deposition (<xref rid="b9-etm-0-0-3312" ref-type="bibr">9</xref>).</p><p>IgA nephropathy in western countries is generally treated by hormone or immunosuppressive therapy, which although effective, is prone to recurrence, hormone dependence and related complications, and other side effects (<xref rid="b3-etm-0-0-3312" ref-type="bibr">3</xref>). In a related study (<xref rid="b4-etm-0-0-3312" ref-type="bibr">4</xref>) it was identified that, for child patients, conservative treatment was able to receive the same curative effects as hormone or hormone combined with immunosuppressive agents, and with fewer complications.</p><p>Eucalyptol-limonene-pinene enteric soft capsule has been developed from the ferulaic acid of ligustrazine, a traditional Chinese medicine. Basic studies (<xref rid="b10-etm-0-0-3312" ref-type="bibr">10</xref>) have confirmed that it may promote circulation and remove stasis, inhibit platelet aggregation, activate meridians and collaterals, and exerts anti-inflammatory and anti-oxidative effects. Its possible mechanisms involve selectively releasing thromboxane synthase, inhibiting the activation of phospholipase A2, reducing the generation of peanut arachidonic acid, improving the level of cyclic AMP, inhibiting activity of phosphodiesterase, inhibiting the expression of growth factors of glomerular mesangial cell connective tissues and synthesis of extracellular matrix, inhibiting the activation of renal fibroblast phenotype, reducing the abnormal expression of IgA in circulation or <italic>in situ</italic>, and inhibiting antigen-antibody complex from precipitating in renal mesangial region (<xref rid="b11-etm-0-0-3312" ref-type="bibr">11</xref>). Another study (<xref rid="b12-etm-0-0-3312" ref-type="bibr">12</xref>) also suggested that piperazine ferulate was effective in nephrotic syndrome and diabetic nephropathy. It may reduce the pressure inside the glomerulus, prevent glomerular sclerosis, inhibit platelet aggregation, anti-coagulation, improve micro-circulation, inhibit cholesterol synthesis, reduce blood lipids, eliminate free radicals and prevent lipid peroxidation injury through the blood vessels constriction and vascular smooth muscle proliferation induced by antagonistic vascular endothelium.</p><p>Eucalyptol-limonene-pinene enteric soft capsule is composed of the extracts of Myrtaceae eucalyptus genus, Rutaceae citrus genus and Pinaceae pine genus plants (<xref rid="b13-etm-0-0-3312" ref-type="bibr">13</xref>). Its main components are eucalyptus, limonene and &#x003b1;-pinene. Eucalyptol-limonene-pinene enteric soft capsule has many effects, such as promoting circulation and removing stasis, inhibiting platelet aggregation, activating meridians and collaterals, and exerting anti-inflammatory and antioxidative effects (<xref rid="b14-etm-0-0-3312" ref-type="bibr">14</xref>). Previous studies have found that the eucalyptol-limonene-pinene enteric soft capsule, as a natural and strongly effective mucus promoting agent, and may significantly improve the respiratory diseases especially symptoms associated with acute exacerbation of chronic bronchitis (<xref rid="b15-etm-0-0-3312" ref-type="bibr">15</xref>). Clinical application has proven that it can reduce the high reactivity of the airway, enhance the body immunity, and reduce the recurrence of respiratory tract infections (<xref rid="b16-etm-0-0-3312" ref-type="bibr">16</xref>).</p><p>The results of the present study have shown that the total effective rate, incidence of complications, serum IgA and fibronectin levels, and levels of complement C3 of the observation group were significantly higher compared to the control group. In conclusion, piperazine ferulate tablets combined with eucalyptol-limonene-pinene enteric soft capsule is safe and effective for the treatment of children with IgA nephropathy. It was superior to conservative or hormonal therapy, and thus worthy of clinical promotion.</p></sec></body><back><ref-list><title>References</title><ref id="b1-etm-0-0-3312"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastings</surname><given-names>MC</given-names></name><name><surname>Moldoveanu</surname><given-names>Z</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Berthoux</surname><given-names>F</given-names></name><name><surname>Julian</surname><given-names>BA</given-names></name><name><surname>Sanders</surname><given-names>JT</given-names></name><name><surname>Renfrow</surname><given-names>MB</given-names></name><name><surname>Novak</surname><given-names>J</given-names></name><name><surname>Wyatt</surname><given-names>RJ</given-names></name></person-group><article-title>Biomarkers in IgA nephropathy: relationship to pathogenetic hits</article-title><source>Expert Opin Med Diagn</source><volume>7</volume><fpage>615</fpage><lpage>627</lpage><year>2013</year><pub-id pub-id-type="doi">10.1517/17530059.2013.856878</pub-id><pub-id pub-id-type="pmid">24175678</pub-id></element-citation></ref><ref id="b2-etm-0-0-3312"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aizawa</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Pang</surname><given-names>H</given-names></name><name><surname>Kihara</surname><given-names>M</given-names></name><name><surname>Nakata</surname><given-names>J</given-names></name><name><surname>Yamaji</surname><given-names>K</given-names></name><name><surname>Horikoshi</surname><given-names>S</given-names></name><name><surname>Tomino</surname><given-names>Y</given-names></name></person-group><article-title>Uncoupling of glomerular IgA deposition and disease progression in alymphoplasia mice with IgA nephropathy</article-title><source>PLoS One</source><volume>9</volume><fpage>e95365</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0095365</pub-id><pub-id pub-id-type="pmid">24743510</pub-id></element-citation></ref><ref id="b3-etm-0-0-3312"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Nakata</surname><given-names>J</given-names></name><name><surname>Sato</surname><given-names>D</given-names></name><name><surname>Kajiyama</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Tomino</surname><given-names>Y</given-names></name></person-group><article-title>Pathological role of tonsillar B cells in IgA nephropathy</article-title><source>Clin Dev Immunol</source><volume>2011</volume><fpage>639074</fpage><year>2011</year><pub-id pub-id-type="doi">10.1155/2011/639074</pub-id><pub-id pub-id-type="pmid">21785618</pub-id></element-citation></ref><ref id="b4-etm-0-0-3312"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiryluk</surname><given-names>K</given-names></name><name><surname>Novak</surname><given-names>J</given-names></name></person-group><article-title>The genetics and immunobiology of IgA nephropathy</article-title><source>J Clin Invest</source><volume>124</volume><fpage>2325</fpage><lpage>2332</lpage><year>2014</year><pub-id pub-id-type="doi">10.1172/JCI74475</pub-id><pub-id pub-id-type="pmid">24892706</pub-id></element-citation></ref><ref id="b5-etm-0-0-3312"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>SJ</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Nephroprotective effects of piperazine ferulate on rat remnant kidney</article-title><source>Chin J Integr Trad West Nephrol</source><volume>3</volume><fpage>256</fpage><lpage>259</lpage><year>2002</year></element-citation></ref><ref id="b6-etm-0-0-3312"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuzawa</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>R</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Katafuchi</surname><given-names>R</given-names></name><name><surname>Tomita</surname><given-names>M</given-names></name><name><surname>Fujigaki</surname><given-names>Y</given-names></name><name><surname>Kitamura</surname><given-names>H</given-names></name><name><surname>Goto</surname><given-names>M</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Urushihara</surname><given-names>M</given-names></name><name><surname>Kondo</surname><given-names>S</given-names></name><name><surname>Kagami</surname><given-names>S</given-names></name><name><surname>Yasuda</surname><given-names>Y</given-names></name><name><surname>Komatsu</surname><given-names>H</given-names></name><name><surname>Takahara</surname><given-names>M</given-names></name><name><surname>Harabuchi</surname><given-names>Y</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Matsuo</surname><given-names>S</given-names></name></person-group><article-title>Evidence-based clinical practice guidelines for IgA nephropathy 2014</article-title><source>Clin Exp Nephrol</source><month>4</month><day>21st</day><year>2016</year><comment>(Epub ahead of print)</comment><pub-id pub-id-type="doi">10.1007/s10157-015-1223-y</pub-id><pub-id pub-id-type="pmid">27095365</pub-id></element-citation></ref><ref id="b7-etm-0-0-3312"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalantari</surname><given-names>S</given-names></name><name><surname>Rutishauser</surname><given-names>D</given-names></name><name><surname>Samavat</surname><given-names>S</given-names></name><name><surname>Nafar</surname><given-names>M</given-names></name><name><surname>Mahmudieh</surname><given-names>L</given-names></name><name><surname>Rezaei-Tavirani</surname><given-names>M</given-names></name><name><surname>Zubarev</surname><given-names>RA</given-names></name></person-group><article-title>Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography</article-title><source>PLoS One</source><volume>8</volume><fpage>e80830</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0080830</pub-id><pub-id pub-id-type="pmid">24339887</pub-id></element-citation></ref><ref id="b8-etm-0-0-3312"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>KN</given-names></name><name><surname>Chan</surname><given-names>LY</given-names></name><name><surname>Tang</surname><given-names>SC</given-names></name><name><surname>Tsang</surname><given-names>AW</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Tse</surname><given-names>KC</given-names></name><name><surname>Yip</surname><given-names>T</given-names></name><name><surname>Leung</surname><given-names>JC</given-names></name></person-group><article-title>Characteristics of polymeric lambda-IgA binding to leukocytes in IgA nephropathy</article-title><source>J Am Soc Nephrol</source><volume>13</volume><fpage>2309</fpage><lpage>2319</lpage><year>2002</year><pub-id pub-id-type="doi">10.1097/01.ASN.0000026497.82930.73</pub-id><pub-id pub-id-type="pmid">12191975</pub-id></element-citation></ref><ref id="b9-etm-0-0-3312"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>JC</given-names></name><name><surname>Tsang</surname><given-names>AW</given-names></name><name><surname>Chan</surname><given-names>DT</given-names></name><name><surname>Lai</surname><given-names>KN</given-names></name></person-group><article-title>Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells</article-title><source>J Am Soc Nephrol</source><volume>11</volume><fpage>241</fpage><lpage>249</lpage><year>2000</year><pub-id pub-id-type="pmid">10665931</pub-id></element-citation></ref><ref id="b10-etm-0-0-3312"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name></person-group><article-title>Sodium ferulate inhibits neointimal hyperplasia in rat balloon injury model</article-title><source>PLoS One</source><volume>9</volume><fpage>e87561</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0087561</pub-id><pub-id pub-id-type="pmid">24489938</pub-id></element-citation></ref><ref id="b11-etm-0-0-3312"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Pei</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Mu</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>The protective effect of sodium ferulate and oxymatrine combination on paraquat-induced lung injury</article-title><source>Iran J Pharm Res</source><volume>14</volume><fpage>573</fpage><lpage>583</lpage><year>2015</year><pub-id pub-id-type="pmid">25901166</pub-id></element-citation></ref><ref id="b12-etm-0-0-3312"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Shang</surname><given-names>L</given-names></name><name><surname>Ping</surname><given-names>AS</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>XJ</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Magdalou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>LB</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>TNF/TNFR signal transduction pathway-mediated anti-apoptosis and anti-inflammatory effects of sodium ferulate on IL-1&#x003b2;-induced rat osteoarthritis chondrocytes in vitro</article-title><source>Arthritis Res Ther</source><volume>14</volume><fpage>R242</fpage><year>2012</year><pub-id pub-id-type="doi">10.1186/ar4085</pub-id><pub-id pub-id-type="pmid">23134577</pub-id></element-citation></ref><ref id="b13-etm-0-0-3312"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>W</given-names></name><name><surname>Fu</surname><given-names>P</given-names></name><name><surname>Zuo</surname><given-names>C</given-names></name><name><surname>Feng</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name></person-group><article-title>General acteoside of Rehmanniae leaves in the treatment of primary chronic glomerulonephritis: A randomized controlled trial</article-title><source>Afr J Tradit Complement Altern Med</source><volume>10</volume><fpage>109</fpage><lpage>115</lpage><year>2013</year><pub-id pub-id-type="pmid">24146510</pub-id></element-citation></ref><ref id="b14-etm-0-0-3312"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyagi</surname><given-names>AK</given-names></name><name><surname>Bukvicki</surname><given-names>D</given-names></name><name><surname>Gottardi</surname><given-names>D</given-names></name><name><surname>Tabanelli</surname><given-names>G</given-names></name><name><surname>Montanari</surname><given-names>C</given-names></name><name><surname>Malik</surname><given-names>A</given-names></name><name><surname>Guerzoni</surname><given-names>ME</given-names></name></person-group><article-title>Eucalyptus essential oil as a natural food preservative: in vivo and in vitro antiyeast potential</article-title><source>Biomed Res Int</source><volume>2014</volume><fpage>969143</fpage><year>2014</year><pub-id pub-id-type="pmid">25177704</pub-id></element-citation></ref><ref id="b15-etm-0-0-3312"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhibi</surname><given-names>S</given-names></name><name><surname>Mbarki</surname><given-names>S</given-names></name><name><surname>Elfeki</surname><given-names>A</given-names></name><name><surname>Hfaiedh</surname><given-names>N</given-names></name></person-group><article-title><italic>Eucalyptus globulus</italic> extract protects upon acetaminophen-induced kidney damages in male rat</article-title><source>Bosn J Basic Med Sci</source><volume>14</volume><fpage>99</fpage><lpage>104</lpage><year>2014</year><pub-id pub-id-type="pmid">24856382</pub-id></element-citation></ref><ref id="b16-etm-0-0-3312"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokaeian</surname><given-names>M</given-names></name><name><surname>Nakhaee</surname><given-names>A</given-names></name><name><surname>Moodi</surname><given-names>B</given-names></name><name><surname>Ali</surname><given-names>Khazaei H</given-names></name></person-group><article-title><italic>Eucalyptus globulus</italic> (eucalyptus) treatment of candidiasis in normal and diabetic rats</article-title><source>Iran Biomed J</source><volume>14</volume><fpage>121</fpage><lpage>126</lpage><year>2010</year><pub-id pub-id-type="pmid">21079663</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tI-etm-0-0-3312" orientation="portrait" position="float"><label>Table I.</label><caption><p>Comparison of total efficiency and the incidence of complications [case (%)].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Case</th><th align="center" valign="bottom" rowspan="1" colspan="1">Excellent<sup><xref rid="tfn1-etm-0-0-3312" ref-type="table-fn">a</xref></sup></th><th align="center" valign="bottom" rowspan="1" colspan="1">Effective<sup><xref rid="tfn2-etm-0-0-3312" ref-type="table-fn">b</xref></sup></th><th align="center" valign="bottom" rowspan="1" colspan="1">Ineffective<sup><xref rid="tfn3-etm-0-0-3312" ref-type="table-fn">c</xref></sup></th><th align="center" valign="bottom" rowspan="1" colspan="1">Total effective rate</th><th align="center" valign="bottom" rowspan="1" colspan="1">Secondary infection</th><th align="center" valign="bottom" rowspan="1" colspan="1">Renal function deterioration</th><th align="center" valign="bottom" rowspan="1" colspan="1">Stress ulcer</th><th align="center" valign="bottom" rowspan="1" colspan="1">Complication<sup><xref rid="tfn4-etm-0-0-3312" ref-type="table-fn">d</xref></sup></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">19 (63.3)</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">10 (33.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Observation</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">26 (86.7)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">3 (10.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> test</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4.356</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4.812</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.037</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.028</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-0-0-3312"><label>a</label><p>Excellent, clinical symptoms disappeared and IgA deposition decreased by &#x0003e;90%.</p></fn><fn id="tfn2-etm-0-0-3312"><label>b</label><p>Effective, clinical symptoms mostly disappeared and IgA deposition decreased by 50&#x02013;80%.</p></fn><fn id="tfn3-etm-0-0-3312"><label>c</label><p>Ineffective, clinical symptoms were not improved.</p></fn><fn id="tfn4-etm-0-0-3312"><label>d</label><p>Complications included IgA secondary hypertension, increased proteinuria, secondary infection, renal function deterioration, and stress ulcer.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tII-etm-0-0-3312" orientation="portrait" position="float"><label>Table II.</label><caption><p>Comparison of serum IgA, fibronectin and complement C3 levels.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1">IgA</th><th align="center" valign="bottom" colspan="2" rowspan="1">Fibronectin (&#x000b5;g/ml)</th><th align="center" valign="bottom" colspan="2" rowspan="1">Complement C3 (g/l)</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-intervention</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-intervention</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-intervention</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-intervention</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-intervention</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post-intervention</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">0.82&#x000b1;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.59&#x000b1;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">430.6&#x000b1;52.3</td><td align="center" valign="top" rowspan="1" colspan="1">328.7&#x000b1;38.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.5&#x000b1;0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.7&#x000b1;0.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Observation</td><td align="center" valign="top" rowspan="1" colspan="1">0.84&#x000b1;0.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.33&#x000b1;0.02</td><td align="center" valign="top" rowspan="1" colspan="1">442.1&#x000b1;46.7</td><td align="center" valign="top" rowspan="1" colspan="1">265.4&#x000b1;30.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.4&#x000b1;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">1.1&#x000b1;0.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t-test</td><td align="center" valign="top" rowspan="1" colspan="1">0.624</td><td align="center" valign="top" rowspan="1" colspan="1">5.032</td><td align="center" valign="top" rowspan="1" colspan="1">0.327</td><td align="center" valign="top" rowspan="1" colspan="1">5.127</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.935</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;5.263</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">0.573</td><td align="center" valign="top" rowspan="1" colspan="1">0.025</td><td align="center" valign="top" rowspan="1" colspan="1">0.128</td><td align="center" valign="top" rowspan="1" colspan="1">0.021</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.763</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.017</td></tr></tbody></table></table-wrap></floats-group></article>